Source:http://linkedlifedata.com/resource/pubmed/id/20381119
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2010-7-13
|
pubmed:abstractText |
CD147, a transmembrane glycoprotein member of the immunoglobulin superfamily of receptors, is involved in invasion and angiogenesis of some types of tumors; but its roles and clinicopathologic significance in pituitary adenomas are not clear. Using immunohistochemistry and quantitative reverse transcriptase polymerase chain reaction, we measured the expression of CD147, matrix metalloproteinase-2, and Ki-67 in 74 pituitary adenomas and evaluated the associations of CD147 with matrix metalloproteinase-2, Ki-67 labeling index, clinicopathologic characteristics, and prognosis. The CD147 protein was expressed in 35 (87.5%) of 40 invasive and in 16 (47.1%) of 34 noninvasive pituitary adenomas; and matrix metalloproteinase-2, in 32 (80.0%) and in 14 (41.2%) of 34, respectively. The Ki-67 labeling index was 3.93% +/- 2.48% for invasive samples and 1.32% +/- 1.04% for noninvasive ones. In addition, the expression of CD147 was positively correlated with matrix metalloproteinase-2, Ki-67 labeling index, or both in invasive pituitary adenomas (P< .01 and P< .01, respectively). All of the 4 recurrent adenomas were concurrently positive for CD147 and matrix metalloproteinase-2, and the Ki-67 labeling indexes of all were greater than 3%. Thus, CD147 may play a pivotal role in the development and progression of invasive pituitary adenomas and also be a useful prognostic biomarker.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1532-8392
|
pubmed:author | |
pubmed:copyrightInfo |
2010 Elsevier Inc. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
41
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1165-71
|
pubmed:meshHeading |
pubmed-meshheading:20381119-Adenoma,
pubmed-meshheading:20381119-Adolescent,
pubmed-meshheading:20381119-Adult,
pubmed-meshheading:20381119-Aged,
pubmed-meshheading:20381119-Antigens, CD147,
pubmed-meshheading:20381119-Female,
pubmed-meshheading:20381119-Humans,
pubmed-meshheading:20381119-Immunohistochemistry,
pubmed-meshheading:20381119-Ki-67 Antigen,
pubmed-meshheading:20381119-Male,
pubmed-meshheading:20381119-Matrix Metalloproteinase 2,
pubmed-meshheading:20381119-Middle Aged,
pubmed-meshheading:20381119-Neoplasm Invasiveness,
pubmed-meshheading:20381119-Pituitary Neoplasms,
pubmed-meshheading:20381119-Prognosis,
pubmed-meshheading:20381119-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:20381119-Tumor Markers, Biological
|
pubmed:year |
2010
|
pubmed:articleTitle |
CD147 expression in pituitary adenomas and its significance for clinical outcome.
|
pubmed:affiliation |
Department of Neurosurgery, Shandong Provincial Hospital, Shandong University, Jinan, 250021, China.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|